117 results about "Long term treatment" patented technology

A radially expandable endoprosthesis device and method of deployment with an at least two stage deployment capability. More particularly, the device pertains to an annularly expandable heart valve prosthesis which is adapted for the long-term treatment of valvular diseases in infants, children and adolescents. The device is constituted of a combination of superelastic alloys and bioresorabable materials which facilitates the devices to undergo multistage deployments at predetermined intervals while emplaced in the body vessels or lumens of patients.

A tinnitus method and device for providing relief to a person suffering from the disturbing effects of tinnitus is described. The method can be implemented entirely in software to spectrally modify an audio signal in accordance with a predetermined masking algorithm which modifies the intensity of the audio signal at selected frequencies. A predetermined masking algorithm is described which provides intermittent masking of the tinnitus wherein, at a comfortable listening level, during peaks of the audio signal the tinnitus is completely obscured, whereas during troughs the perception of the tinnitus occasionally emerges. In practice it has been found that such intermittent masking provides an immediate sense of relief, control and relaxation for the person, whilst enabling sufficient perception of the tinnitus for habituation and long term treatment to occur. Advantageously the predetermined masking algorithm is specifically tailored to the audiometric configuration of the person. For example, the masking algorithm may be partly tailored to the hearing loss characteristic of the person. A tinnitus rehabilitation device used in conjunction with a personal sound reproducing system is also described.

A tinnitus method and device for providing relief to a person suffering from the disturbing effects of tinnitus is described. The method can be implemented entirely in software to spectrally modify an audio signal in accordance with a predetermined masking algorithm which modifies the intensity of the audio signal at selected frequencies. A predetermined masking algorithm is described which provides intermittent masking of the tinnitus wherein, at a comfortable listening level, during peaks of the audio signal the tinnitus is completely obscured, whereas during troughs the perception of the tinnitus occasionally emerges. In practice it has been found that such intermittent masking provides an immediate sense of relief, control and relaxation for the person, whilst enabling sufficient perception of the tinnitus for habituation and long term treatment to occur. Advantageously the predetermined masking algorithm is specifically tailored to the audiometric configuration of the person. For example, the masking algorithm may be partly tailored to the hearing loss characteristic of the person. A tinnitus rehabilitation device used in conjunction with a personal sound reproducing system is also described.

Methods, systems and devices are described for temporarily or permanently evacuating stagnating air from a diseased lung area, typically for the purpose of treating COPD. Evacuation is accomplished by displacing the stagnant CO2-rich air with a readily diffusible gas using a transluminal indwelling catheter specially configured to remain anchored in the targeted area for long term treatment without supervision. Appropriate elevated positive gas pressure in the targeted area is then regulated via the catheter and a pneumatic control unit to force under positive pressure effusion of the diffusible gas out of the area into neighboring areas while inhibiting infusion of other gases thus effecting a gradual gas volume decrease and deflation of the targeted area.

Systems and methods screen and / or treat disorders of the body using neurostimulation. A trial system implants a temporary or permanent percutaneous lead and couples the lead to an external pulse generator. The external pulse generator supplies a prescribed stimulation regime through the lead to a targeted tissue region. If an improvement in the treated disorder is achieved, use of the trial system may be continued, or an implantable system may be implanted.

The present invention is related to mammalian nutrition and effects thereof in individuals with age associated cognitive decline such as Age Associated Memory Inpairment (AAMI) or a dementing illness such as Alzheimer's disease or related dementia, or Mild Cognitive Impairment, such as improving performance in, or reversal, prevention, reducing and delaying decline in, one or more of cognitive function, memory, behavior, cerebrovascular function, motor function, and / or brain physiology are seen. In particular, the present invention utilizes medium chain triglycerides, in one embodiment, administered as part of a long-term treatment regimen, to preserve or improve learning, attention, motor performance, cerebrovascular function, social behavior, and to increase activity levels, particularly in aging mammals.

Disclosed are methods for the use of therapeutic polypeptide-encoding polynucleotides in the creation of transformed host cells and transgenic animals is disclosed. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions comprising polynucleotide sequences that express one or more mammalian PEDF or anti-angiogenesis polypeptides is described. In particular, the invention provides gene therapy methods for the prevention, long-term treatment and / or amelioration of symptoms of a variety of conditions and disorders in a mammalian eye, including, for example blindness, loss of vision, retinal degeneration, macular degeneration, and related disorders resulting from retinal or choroidal neovascularization in affected individuals.

Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compositions 10 are designed to exhibit such bioavailability, which is effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compositions reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy.

In brachytherapy where position information relating to a radiation source is to be generated, a guidance system is adapted to acquire and process position data or position and tissue data, so that high-precision interventional radiotherapy can be carried out, especially according to a dose plan and for intra-fraction monitoring for a therapy plan or adaptive re-planning. The data can be stored and used to refine future treatment plans and for future correlation with long-term treatment outcome, especially in context with low energy brachytherapy.

The invention relates to montelukast sodium chewing tablets and a preparation process thereof. The tablets comprise montelukast sodium and a filling agent, a diluting agent, a bonding agent, a disintegrating agent, and a flavoring. The tablets are prepared with a powder direct tabletting method. The fluidity and compressibility are good. The chewing tablets have long-term storage stability. The tablets are used in prevention and long-term treatment of asthma of children aged 2 to 14, and are used in relieving symptoms caused by allergic rhinitis.

Cardiomyopathy may be treated by distributing space-occupying agent within the myocardium in a pattern about one or more chambers of the heart, such that the space-modifying agent integrates into and thickens at least part of the cardiac wall about the chamber so as globally to reduce wall stress and stabilize or even reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function. Over time the relief of wall stress reduces oxygen consumption and promotes healing. Moreover, various long-term therapeutic effects may be realized depending on the properties of the space-occupying agent, including combinations with other therapeutic materials. Specific cardiac conditions treatable by these systems and methods include, for example, dilated cardiomyopathy (with or without overt aneurismal formations), congestive heart failure, and ventricular arrhythmias. Patterns of distribution of space-occupying agent within the myocardium for global resizing may also be used or augmented to treat localized conditions such as myocardial infarctions, overt aneurysm of the ventricular wall as typically forms in response to large transmural myocardial infarctions, and mitral regurgitation due to a noncompliant mitral valve. These techniques may also be used to treat localized conditions that may not yet have progressed to cardiomyopathy.

The present invention relates to a controlled-release niacin formulation. In particular, the present invention relates to a controlled-release niacin formulation, comprising niacin; hydroxypropyl methylcellulose; and a carboxyvinyl polymer, in which the carboxyvinyl polymer and hydroxypropyl methylcellulose are contained in a predetermined weight ratio, and to a preparation method thereof.The controlled-release niacin formulation according to the present invention maintains its matrix shape until completion of release, and maintains its release pattern without fluctuation for a desired time period, unlike a commercial formulation. In particular, since niacin formulations are used for long-term treatment of hyperlipidemia, the controlled-release niacin formulation of the present invention, capable of maintaining effective blood concentration and high stability for a long period of time, is very useful.

Methods and devices are presented for the long-term treatment of a patient infectious with deadly microbes without a risk for spread of germs to caregivers comprising a hermetically sealed human sized containment box with means for delivering medical care, for sustaining life, and for dealing with waste products, as well as providing rehabilitative care.

The invention relates to an attapulgite clay composite cyanobacteria-eutrophication water treatment agent, which is a special sewage treatment agent in the fields of environmental protection and environmental treatment. According to the present invention, attapulgite clay, bentonite and natural zeolite are subjected to activation and modification and other high-tech deep processing, and are scientifically compounded with organic reagents to prepare the attapulgite clay composite cyanobacteria-eutrophication water treatment agent, which centralizes special properties of a plurality of minerals and organic additives; the treatment agent is mainly used for cyanobacteria outbreak emergency treatments of lakes, reservoirs, rivers, landscape water and the like, and eutrophication long-term treatments; the treatment agent is an innovative method for ecological restoration and resource; the treatment agent further can be used for heavy metal contaminated water treatments, wherein the heavy metals comprise arsenic, lead and the like; the treatment agent is adopted in the cyanobacteria outbreak in Tai lake of Jiangsu, Chao lake of Anhui and the like, cyanobacteria-eutrophication water multiple sampling and field treatment tests, the results show that: the treatment agent has characteristics of good treatment effect, convenient operation and low cost; the treatment agent can be adopted as the emergency agent and the long-term agent, and can treat both manifestation and root cause; the pumped sludge can be adopted as high-quality green fertilizer, such that the waste is changed into wealth so as to realize the ecological restoration and the resource recycling economy.

The invention discloses a composite biological matrix for glaucoma surgery and a preparation method thereof. The composite biological matrix has a double-layer composite structure formed by aging and freeze-drying a compact base material layer and a loose layer coated on the compact base material layer, wherein the compact base material layer is a cross-linked denuded amniotic membrane or animal tissue membrane, and the loose layer is a porous membrane prepared from a biological macromolecular material. The composite biological matrix is prepared by multiple times of cross-linking modification, so that the retention time of the composite biological matrix in vivo is significantly prolonged, the effect of stably preventing scarring for a long term is achieved, and the long-term treatment effect after filtering surgery can be effectively improved.

The invention relates to injectable long-acting insulin formulations for the treatment of types I and II diabetes in humans and animals.The essential object of the invention is to provide an injectable long-acting insulin formulation in the form of a colloidal suspension which is stable, which has a good local tolerance and toxicity compatible with the chronic treatment of diabetics, and which maintains a substantial hypoglycemic effect extending over at least 24 hours after a single administration, e.g. by the subcutaneous route.To achieve this object, the invention relates to a stable aqueous colloidal formulation of insulin-laden nanoparticles of at least one poly(Leu-block-Glu) in which the pH is between 5.8 and 7.0, the osmolarity O (in mOsmol) . . . : 270≦O≦800, and the viscosity v (in mPa.s) is low, namely v≦40. The nanoparticles of poly(Leu-block-Glu) have a mean hydrodynamic diameter Dh such that: 15≦Dh≦40.The invention relates to an antidiabetic drug based on this long-acting insulin formulation and injectable using needles of gauge 29G, 30G or 31G.

The invention relates to a medicine for treating tumor and hemorrhoid and a manufacturing method thereof. The medicine aims at the disadvantages that: the prior treatment method for removing the hemorrhoid and the tumor can only kill or remove partial tumor cells, has large pain and high recurrence rate during the treatment period, has the phenomena of lassitude, hypodynamia, nausea, vomiting and hemogram reduction during the radiotherapy period, causes low immunity, damages self-immunologic function of a human body, inhibits functions of bone marrow stem cells, is easy to produce drug dependence, and is easy for recurrence. The invention prepares tannic acid, atropine, gallic acid, quinin hydrochloride, ferrous sulfate, caffeine, pure sulfuric acid, urethane, carbolic acid, sterile water and the like, into medicines for local parts of pathological changes, does not hurt normal tissues, has no pain, does not need to treat for a long time, and has the advantages of taking effect by injecting at one time, no recurrence, wide raw materials, low cost, wide clinical application, and small side effect.

The invention belongs to an external thermal therapy bag made of traditional Chinese medicine for external application for treating aches and pains in human necks, shoulders, waists and legs. The conventional treatment includes medication, physical treatment, acupuncture, massage and the like. The treatment with western medicaments is usually implemented by using analgesic antipyretics which can relieve aches and pains temporarily, but are not suitable for long-term treatment. The aim of the invention is to treat aches and pains in necks, shoulders, waists and legs by combining a traditional Chinese medicinal formula and mineral elements. The 14 kinds of raw material medicaments of the external thermal therapy bag include myrrh, szechuan lovage rhizome, pepper, incised notopterygium rhizome, garden balsam stem, unprocessed radix aconite and the like; the raw material medicaments are crushed, screened and uniformly mixed with sodium chloride natural mineral element particles; and the mixed is filled into a cloth bag made of pure cotton, and cloth bag is sealed to be used as external thermal therapy bag for heating. The external thermal therapy bag has the advantages that: the clinic treatment of 208 people with cervical spondylosis show that the rate of effectiveness is 47.60 percent and that the total rate of effectiveness is up to 97.67 percent; and the aches and pains in necks, shoulders, waists and legs, which are caused by cervical spondylosis, scapulohumeral periarthritis, lumbar muscle strain, protrasion of the lumbar intervertebral disci, soft tissue injury and the like can be cured effectively.

The invention discloses a semi-interpenetrating network nano hybrid hydrogel and a preparation method and an application thereof. Firstly, chitosan is modified to prepare water soluble carboxymethyl chitosan (CMCS); then N-isopropylacrylamide (NIPAM), CMCS and (carboxyl functionalized) carbon nanotubes are subjected to in-situ free radical crosslinking polymerization reaction, and the semi-interpenetrating network nano hybrid hydrogel with different composition ratios of NIPAM, CMCS and the nanotubes is obtained. The prepared novel nano hybrid hydrogel has relatively high swelling rate, appropriate volume phase transition temperature and pH phase transition point, and high drug loading amount and continuous controllable drug release behavior. The hydrogel pharmaceutical preparation can be used as a promising hydrophilic oral drug carrier, is used for targeted release of oral vaccines, polypeptides, proteins and anticancer drugs, has low toxicity, and can be used for long-term treatment of colon cancer and the like.

Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compositions 10 are designed to exhibit such bioavailability, which is effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compositions reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy.

The present invention refers to drugs resulting from the pharmaceutical substance diclofenac, relative to the formula. The invention further refers to a pharmaceutical composition, which involves the said drugs and a pharmaceutically adequate vehicle. It is also described a method for the treatment of inflammation through the administration of the new drugs in patients with gastric problems or subjected to long-term treatments.

The present invention is related to mammalian nutrition and effects thereof in individuals with age associated cognitive decline such as Age Associated Memory Impairment (AAMI) or a dementing illness such as Alzheimer's disease or related dementia, or Mild Cognitive Impairment, such as improving performance in, or reversal, prevention, reducing and delaying decline in, one or more of cognitive function, memory, behavior, cerebrovascular function, motor function, and / or brain physiology are seen. In particular, the present invention utilizes medium chain triglycerides, in one embodiment, administered as part of a long-term treatment regimen, to preserve or improve learning, attention, motor performance, cerebrovascular function, social behavior, and to increase activity levels, particularly in aging mammals.

The invention discloses a Chinese herbal preparation for treating chronic pharyngitis. The Chinese herbal preparation is prepared from the following raw materials by weight parts: 1 to 100 parts of honeysuckle or lonicera confusa DC, 1 to 98 parts of ophiopogon root or 1 to 98 parts of asparagus, 1 to 98 parts of figwort and 1 to 80 parts of liquorice. Proved by a plurality of experiments, the Chinese herbal preparation of the invention has favorable effects on treating the chronic pharyngitis and can have certain treatment effects in a short period, and patients can be cured after long-term treatment, thereby consuming less time. The Chinese herbal preparation has the functions of promoting the secretion of saliva and nourishing body as well as diminishing inflammation and easing pain, can increase the body immunity and can improve the blood factor disorder caused by the chronic pharyngitis. The Chinese herbal preparation has favorable effects on treating the chronic pharyngitis caused by fire due to yin deficiency.

The invention discloses a sustained-release microsphere to achieve the aims of contraception and long-term treatment of endometriosis uterine, which comprises the following components: (1) nomegestrol acetate or analogs thereof, and (2) a biodegradable polymer, wherein the weight ratio of an ester-terminated polymer to a carboxyl-terminated polymer is between 1:0.01-1:1; the ester-terminated polymer is selected from polylactide-glycolide, polylactide, poly-beta-hydroxybutyrate, poly ortho ester, polycaprolactone, poly-phosphate, polyanhydride, or poly-cyanoacrylate; the carboxyl-terminated polymer is selected from polyglycolic acid and polylactic acid-glycolic acid; and the weight of the nomegestrol acetate or the analogs thereof accounts for 5 to 80 percent of the total weight of the microsphere. The invention also discloses a preparation method and application of the sustained-release microsphere.

The invention discloses an application of metformin hydrochloride sustained-release tablets in the treatment of type 2 diabetes. The metformin hydrochloride sustained-release tablets are prepared from the following raw materials and adjuvants of (wt%): metformin hydrochloride 42-60, hydroxypropyl methylcellulose 34-50, sodium carboxymethyl cellulose 2-5, microcrystalline cellulose 1-3, and magnesium stearate 2-4. The tablets can be made by directly adding microcrystalline cellulose powder into granule, mixing and tabletting to reduce the dosage of the hydroxypropyl methylcellulose and the sodium carboxymethyl cellulose, resulting in a simple and convenient production method. The sustained-release tablets can effectively control and release drug at a certain speed, so as to reduce drug peak concentration in blood, reduce administration frequency and dosage, reduce adverse reactions, and be in favor of long-term treatment for patients with type 2 diabetes. The sustained-release tablets have hyperglycemia treating, hypoglycemia preventing, blood lipid reducing, and weight gain preventing effects.

The invention relates to a method for the treatment of an oestrogen-dependent proliferative disorder of the uterus such as endometriosis and uterine fibroids in a patient, by administering an aromatase inhibitor to the patient intravaginally. This achieves high local levels of aromatase inhibitor Locally, and therefore avoids some of the adverse reactions that are observed when aromatase inhibitors are delivered orally. Further, intravaginal delivery allows inhibition of the local lesional production without significantly affecting the circulating levels which have been produced by the ovaries. This results in minimal side-effects and will allow for longer term treatment than current therapies.

Methods and devices are presented for the long-term treatment of a patient infectious with deadly microbes without a risk for spread of germs to caregivers comprising a hermetically sealed human sized containment box with means for delivering medical care, for sustaining life, and for dealing with waste products, as well as providing rehabilitative care.

The invention provides a medicine for treating gout, in particular relates to a particle for eliminating turbidity and treating arthralgia, which is prepared from rhizoma smilacis glabrae, coix seed, red peony root and caulis lonicerae. The particle is used for clinically treating acute gout, does not have side effects caused by treatment of Western medicines, has obvious effects on resisting inflammation and relieving pain, and has strong medical effect and lasting action. The short-term treatment effect of the particle is equivalent to the short-term treatment effect of Western medicine colchicine, and the long-term treatment effect of the particle is better than the long-term treatment effect of the colchicine.